Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Sanz G, Stauder R, Holm MS, Mittelman M, Mądry K, Malcovati L, Tatic A, Almeida AM, Germing U, Savic A, Gredelj Šimec N, Culligan D, Itzykson R, Guerci-Bresler A, Slama B, van de Loosdrecht A, van Marrewijk C, Droste J, Blijlevens N, van Kraaij M, Bowen D, de Witte T, Smith A; EUMDS Registry Participants.

Haematologica. 2019 Jul 5. pii: haematol.2018.212332. doi: 10.3324/haematol.2018.212332. [Epub ahead of print]

2.

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.

de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Stauder R, Sanz G, Mittelman M, Holm MS, Malcovati L, Mądry K, Germing U, Tatic A, Savic A, Almeida AM, Gredelj-Šimec N, Guerci-Bresler A, Beyne-Rauzy O, Culligan D, Kotsianidis I, Itzykson R, van Marrewijk C, Blijlevens N, Bowen D, de Witte T; EUMDS Registry Participants.

Haematologica. 2019 Jun 6. pii: haematol.2018.212217. doi: 10.3324/haematol.2018.212217. [Epub ahead of print]

3.

Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.

Barrington SF, Phillips EH, Counsell N, Hancock B, Pettengell R, Johnson P, Townsend W, Culligan D, Popova B, Clifton-Hadley L, McMillan A, Hoskin P, O'Doherty MJ, Illidge T, Radford J.

J Clin Oncol. 2019 Jul 10;37(20):1732-1741. doi: 10.1200/JCO.18.01799. Epub 2019 May 21.

PMID:
31112475
4.

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.

Itzykson R, Crouch S, Travaglino E, Smith A, Symeonidis A, Hellström-Lindberg E, Sanz G, Čermák J, Stauder R, Elena C, Germing U, Mittelman M, Langemeijer S, Mądry K, Tatic A, Holm MS, Almeida AM, Savic A, Šimec NG, Luño E, Culligan D, Guerci-Bresler A, Malcovati L, van Marrewijk C, Bowen D, de Witte T, Fenaux P; European MDS Registry members.

Blood Adv. 2018 Aug 28;2(16):2079-2089. doi: 10.1182/bloodadvances.2018020495.

5.

Combined linkage and association analysis of classical Hodgkin lymphoma.

Lawrie A, Han S, Sud A, Hosking F, Cezard T, Turner D, Clark C, Murray GI, Culligan DJ, Houlston RS, Vickers MA.

Oncotarget. 2018 Apr 17;9(29):20377-20385. doi: 10.18632/oncotarget.24872. eCollection 2018 Apr 17.

6.

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.

de Swart L, Smith A, Haase D, Fenaux P, Symeonidis A, Cermak J, Sanz G, Stauder R, Mittelman M, Hellström-Lindberg E, Malcovati L, Langemeijer S, Skov-Holm M, Mądry K, Germing U, Almeida AM, Tatic A, Savic A, Šimec NG, van Marrewijk C, Guerci-Bresler A, Sanhes L, Luño E, Culligan D, Beyne-Rauzy O, Burgstaller S, Blijlevens N, Bowen D, de Witte T.

Leuk Res. 2018 Apr;67:21-26. doi: 10.1016/j.leukres.2018.01.022. Epub 2018 Jan 31.

7.

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.

de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, Tatic A, Symeonidis A, Huls G, Cermak J, van de Loosdrecht AA, Garelius H, Culligan D, Macheta M, Spanoudakis M, Panagiotidis P, Krejci M, Blijlevens N, Langemeijer S, Droste J, Swinkels DW, Smith A, de Witte T; EUMDS Steering Committee.

Haematologica. 2018 Jan;103(1):69-79. doi: 10.3324/haematol.2017.171884. Epub 2017 Nov 9.

8.

Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.

Eyre TA, Osborne WL, Gallop-Evans E, Ardeshna KM, Kassam S, Sadullah S, Sidra G, Culligan D, Arumainathan A, Shankara P, Bowles KM, Eyre DW, Peng YY, Pettengell R, Bloor A, Vandenberghe E, Collins GP.

Br J Haematol. 2018 May;181(4):555-559. doi: 10.1111/bjh.14665. Epub 2017 Mar 24. No abstract available.

PMID:
28342183
9.

Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy.

Ali S, Jones GL, Culligan DJ, Marsden PJ, Russell N, Embleton ND, Craddock C; British Committee for Standards in Haematology.

Br J Haematol. 2015 Aug;170(4):487-95. doi: 10.1111/bjh.13554. Epub 2015 Jun 17.

PMID:
26081614
10.

Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S.

N Engl J Med. 2015 Apr 23;372(17):1598-607. doi: 10.1056/NEJMoa1408648.

11.

Tumour lysis syndrome: new territory for a familiar foe?

Graves E, Culligan D.

Br J Haematol. 2015 Jun;169(5):609-10. doi: 10.1111/bjh.13402. Epub 2015 Mar 30. No abstract available.

PMID:
25824526
12.

Guidelines for the first line management of classical Hodgkin lymphoma.

Follows GA, Ardeshna KM, Barrington SF, Culligan DJ, Hoskin PJ, Linch D, Sadullah S, Williams MV, Wimperis JZ; British Committee for Standards in Haematology.

Br J Haematol. 2014 Jul;166(1):34-49. doi: 10.1111/bjh.12878. Epub 2014 Apr 9. No abstract available.

PMID:
24712411
13.

Guidelines for the diagnosis and management of adult myelodysplastic syndromes.

Killick SB, Carter C, Culligan D, Dalley C, Das-Gupta E, Drummond M, Enright H, Jones GL, Kell J, Mills J, Mufti G, Parker J, Raj K, Sternberg A, Vyas P, Bowen D; British Committee for Standards in Haematology.

Br J Haematol. 2014 Feb;164(4):503-25. doi: 10.1111/bjh.12694. Epub 2013 Dec 23. No abstract available.

PMID:
24372298
14.

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.

Dennis M, Culligan D, Karamitros D, Vyas P, Johnson P, Russell NH, Cavenagh J, Szubert A, Hartley S, Brown J, Bowen D.

Leuk Res Rep. 2013 Aug 28;2(2):70-4. doi: 10.1016/j.lrr.2013.07.003. eCollection 2013.

15.

Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot-Leyden crystals.

Taylor G, Ivey A, Milner B, Grimwade D, Culligan D.

Int J Hematol. 2013 Sep;98(3):267-8. doi: 10.1007/s12185-013-1394-9. Epub 2013 Jul 25.

PMID:
23884732
17.

A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly.

Hay AE, Lawrie A, Robinson N, Dong B, Culligan DJ.

J Clin Apher. 2013 Oct;28(5):378-80. doi: 10.1002/jca.21274. Epub 2013 Mar 11.

PMID:
23483573
18.

Acute myeloid leukemia presenting in a mother and daughter pair with the identical acquired karyotypic abnormality consisting of inversion 3q21q26 and monosomy 7: a review of possible mechanisms.

Lawrie A, Stevenson DA, Doig TN, Vickers MA, Culligan DJ.

Cancer Genet. 2012 Nov;205(11):599-602. doi: 10.1016/j.cancergen.2012.09.001. Epub 2012 Oct 12.

PMID:
23064135
19.

Factors affecting decision making about fertility preservation after cancer diagnosis: a qualitative study.

Peddie VL, Porter MA, Barbour R, Culligan D, MacDonald G, King D, Horn J, Bhattacharya S.

BJOG. 2012 Aug;119(9):1049-57. doi: 10.1111/j.1471-0528.2012.03368.x. Epub 2012 May 30.

20.

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.

Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K, Virchis A, Hills RK, Milligan D; AML Working Group of the UK National Cancer Research Institute.

Br J Haematol. 2012 Aug;158(4):519-22. doi: 10.1111/j.1365-2141.2012.09165.x. Epub 2012 May 29.

PMID:
22639959
21.

Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study.

Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, Culligan D, Galloway MJ, Wood KM, McNally RJ, James PW, Goodlad JR.

Blood. 2012 Jun 21;119(25):6005-15. doi: 10.1182/blood-2011-12-396556. Epub 2012 May 10.

22.

Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia.

Jovanovic JV, Rennie K, Culligan D, Peniket A, Lennard A, Harrison J, Vyas P, Grimwade D.

Front Oncol. 2011 Oct 25;1:35. doi: 10.3389/fonc.2011.00035. eCollection 2011.

23.

Being underweight may reduce your ability to mobilise peripheral blood stem cells.

Crowther M, Avenell A, Culligan DJ.

Transfus Apher Sci. 2010 Dec;43(3):365-7. doi: 10.1016/j.transci.2010.10.010. Epub 2010 Oct 28.

PMID:
21035397
24.

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.

Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy J, McMullin MF, Hunter A, Das-Gupta E, Clark R, Carr R, Hills RK.

J Clin Oncol. 2010 May 10;28(14):2389-95. doi: 10.1200/JCO.2009.26.4242. Epub 2010 Apr 12.

PMID:
20385984
25.

The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control.

Proctor SJ, Lennard AL, Jackson GH, Jones GL, Lewis J, Wilkinson J, White J, Sieniawski M, McKay P, Culligan D, Lucraft HH.

Ann Oncol. 2010 Feb;21(2):426-8. doi: 10.1093/annonc/mdp527. Epub 2009 Nov 9. Review. No abstract available.

PMID:
19901016
26.

Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation.

Crowther M, Avenell A, Culligan DJ.

Bone Marrow Transplant. 2009 Oct;44(7):413-25. doi: 10.1038/bmt.2009.41. Epub 2009 Mar 9. Review.

PMID:
19270730
27.

Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma.

Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA.

Blood. 2008 Jun 1;111(11):5359-70. doi: 10.1182/blood-2007-08-105395. Epub 2008 Feb 27.

28.

A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura.

Mittal S, Blaylock MG, Culligan DJ, Barker RN, Vickers MA.

Haematologica. 2008 Jan;93(1):151-2. doi: 10.3324/haematol.11822.

29.
30.

Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin.

Lim ZY, Killick S, Germing U, Cavenagh J, Culligan D, Bacigalupo A, Marsh J, Mufti GJ.

Leukemia. 2007 Jul;21(7):1436-41. Epub 2007 May 17.

PMID:
17507999
31.

The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma.

Marshall NA, Culligan DJ, Tighe J, Johnston PW, Barker RN, Vickers MA.

Exp Hematol. 2007 Apr;35(4):596-604.

PMID:
17379070
32.

An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation.

Vassiliou GS, Campbell PJ, Li J, Roberts I, Swanton S, Huntly BJ, Fourouclas N, Baxter EJ, Munro LR, Culligan DA, Scott LM, Green AR.

Haematologica. 2006 Aug;91(8):1100-4.

33.

Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia.

Bowen D, Hyslop A, Keenan N, Groves M, Culligan D, Johnson P, Shaw A, Geddes F, Evans P, Porter J, Cavill I.

Haematologica. 2006 May;91(5):709-10.

34.

A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.

Mittal S, Milner BJ, Johnston PW, Culligan DJ.

Eur J Haematol. 2006 Jun;76(6):531-4. Epub 2006 Mar 17.

PMID:
16548918
35.

Thalidomide therapy for low-risk Myelodysplasia.

Bowen D, MacIlwaine L, Cavanagh J, Killick S, Culligan D, Thomson E, Mufti G.

Leuk Res. 2005 Feb;29(2):235-6. No abstract available.

PMID:
15607375
36.

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.

Rao S, Watkins D, Cunningham D, Dunlop D, Johnson P, Selby P, Hancock BW, Fegan C, Culligan D, Schey S, Morris TC, Lissitchkov T, Oliver JW, Holmlund JT.

Ann Oncol. 2004 Sep;15(9):1413-8.

PMID:
15319248
37.

Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma.

Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA.

Blood. 2004 Mar 1;103(5):1755-62. Epub 2003 Nov 6.

38.

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan DW.

Blood. 2003 Dec 15;102(13):4277-83. Epub 2003 Aug 21.

39.

Use of recombinant factor VIIa in life-threatening bleeding following autologous peripheral blood stem cell transplantation complicated by platelet refractoriness.

Culligan DJ, Salamat A, Tait J, Westland G, Watson HG.

Bone Marrow Transplant. 2003 Jun;31(12):1183-4. No abstract available.

PMID:
12796803
41.

Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.

Chee YL, Vickers MA, Stevenson D, Holyoake TL, Culligan DJ.

Leukemia. 2003 Mar;17(3):634-5. No abstract available.

PMID:
12646955
42.

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.

Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J; UK MDS Guidelines Group.

Br J Haematol. 2003 Jan;120(2):187-200. No abstract available.

PMID:
12542475
43.

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.

Gordon S, Helfrich MH, Sati HI, Greaves M, Ralston SH, Culligan DJ, Soutar RL, Rogers MJ.

Br J Haematol. 2002 Nov;119(2):475-83.

PMID:
12406088
44.

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.

Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, Clark FJ, Hunt L, Yin J, Fuller S, Vandenberghe E, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter A, Chopra R, Davies A, Towlson K, Williams CD.

Blood. 2002 Nov 1;100(9):3108-14.

45.

Transfusion-associated graft-versus-host disease in a patient with Waldenstrom's macroglobulinaemia.

Munro LR, Culligan DJ, Grant A, Johnston PW, Watson HG.

Vox Sang. 2002 Oct;83(3):279-81.

PMID:
12366774
46.

Successful salvage of relapsed adults Wilms' tumour with high dose chemotherapy and autologous peripheral blood stem cell rescue.

Petty R, Culligan D, Bissett D.

Clin Oncol (R Coll Radiol). 2002 Aug;14(4):329. No abstract available.

PMID:
12206646
47.

Blastic variant of mantle cell lymphoma occurring in immunosuppressed patients.

Munro LR, Johnston PW, Goodlad JR, Culligan DJ.

Leukemia. 2002 Sep;16(9):1888-9; author reply 1889. No abstract available.

48.

The bioavailability of oral fludarabine phosphate is unaffected by food.

Oscier D, Orchard JA, Culligan D, Cunningham D, Johnson S, Parker A, Klein M, Gieschen H.

Hematol J. 2001;2(5):316-21.

PMID:
11920267
49.

H RAS mutations in haematologically normal individuals.

Taylor C, Larghero J, Thomas C, Warren N, Carter G, Hughes D, Culligan D, Al-Sabah A, Whittaker JA, Chomienne C, Padua RA.

Hematol J. 2000;1(6):399-402.

PMID:
11920220
50.

Inferior vena cava malformation as a risk factor for deep venous thrombosis in the young.

Chee YL, Culligan DJ, Watson HG.

Br J Haematol. 2001 Sep;114(4):878-80.

PMID:
11564079

Supplemental Content

Loading ...
Support Center